Entrada Therapeutics, Inc. Common Stock
TRDA
TRDA: Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
moreShow TRDA Financials
Recent trades of TRDA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TRDA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Cell penetrating peptides and methods of making and using thereof Jan. 18, 2022
-
Patent Title: Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy Nov. 09, 2021
-
Patent Title: Cell penetrating peptides and methods of making and using thereof Oct. 27, 2020
Federal grants, loans, and purchases
Followers on TRDA's company Twitter account
Number of mentions of TRDA in WallStreetBets Daily Discussion
Recent insights relating to TRDA
Recent picks made for TRDA stock on CNBC
ETFs with the largest estimated holdings in TRDA
Flights by private jets registered to TRDA